172 related articles for article (PubMed ID: 29618584)
1. Leflunomide Increases Hepatic Exposure to Methotrexate and Its Metabolite by Differentially Regulating Multidrug Resistance-Associated Protein Mrp2/3/4 Transporters via Peroxisome Proliferator-Activated Receptor
Wang L; Ma L; Lin Y; Liu X; Xiao L; Zhang Y; Xu Y; Zhou H; Pan G
Mol Pharmacol; 2018 Jun; 93(6):563-574. PubMed ID: 29618584
[TBL] [Abstract][Full Text] [Related]
2. Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide.
van der Heijden JW; Oerlemans R; Tak PP; Assaraf YG; Kraan MC; Scheffer GL; van der Laken CJ; Lems WF; Scheper RJ; Dijkmans BA; Jansen G
Arthritis Rheum; 2009 Mar; 60(3):669-77. PubMed ID: 19248091
[TBL] [Abstract][Full Text] [Related]
3. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.
Vlaming ML; van Esch A; Pala Z; Wagenaar E; van de Wetering K; van Tellingen O; Schinkel AH
Mol Cancer Ther; 2009 Dec; 8(12):3350-9. PubMed ID: 19996279
[TBL] [Abstract][Full Text] [Related]
4. Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.
Vlaming ML; Pala Z; van Esch A; Wagenaar E; van Tellingen O; de Waart DR; Oude Elferink RP; van de Wetering K; Schinkel AH
Clin Cancer Res; 2008 Dec; 14(24):8152-60. PubMed ID: 19088030
[TBL] [Abstract][Full Text] [Related]
5. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.
Vlaming ML; Pala Z; van Esch A; Wagenaar E; de Waart DR; van de Wetering K; van der Kruijssen CM; Oude Elferink RP; van Tellingen O; Schinkel AH
Clin Cancer Res; 2009 May; 15(9):3084-93. PubMed ID: 19383815
[TBL] [Abstract][Full Text] [Related]
6. Leflunomide increased the renal exposure of acyclovir by inhibiting OAT1/3 and MRP2.
Liao XY; Deng QQ; Han L; Wu ZT; Peng ZL; Xie Y; Wang GJ; Aa JY; Pan GY
Acta Pharmacol Sin; 2020 Jan; 41(1):129-137. PubMed ID: 31341258
[TBL] [Abstract][Full Text] [Related]
7. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate.
Vlaming ML; van Esch A; van de Steeg E; Pala Z; Wagenaar E; van Tellingen O; Schinkel AH
Drug Metab Dispos; 2011 Aug; 39(8):1338-44. PubMed ID: 21566011
[TBL] [Abstract][Full Text] [Related]
8. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
9. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha.
De Stefano R; Frati E; Nargi F; Baldi C; Menza L; Hammoud M; Galeazzi M
Clin Rheumatol; 2010 May; 29(5):517-24. PubMed ID: 20082236
[TBL] [Abstract][Full Text] [Related]
10. Liver toxicity is rare in rheumatoid arthritis patients using combination therapy with leflunomide and methotrexate.
Alves JA; Fialho SC; Morato EF; Castro GR; Zimmermann AF; Ribeiro GG; Neves FS; Pereira IA
Rev Bras Reumatol; 2011; 51(2):141-4. PubMed ID: 21584420
[TBL] [Abstract][Full Text] [Related]
11. The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis.
Bird P; Griffiths H; Tymms K; Nicholls D; Roberts L; Arnold M; Burnet S; de Jager J; Scott J; Zochling J; Littlejohn G
J Rheumatol; 2013 Mar; 40(3):228-35. PubMed ID: 23322457
[TBL] [Abstract][Full Text] [Related]
12. Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4.
El-Sheikh AA; Greupink R; Wortelboer HM; van den Heuvel JJ; Schreurs M; Koenderink JB; Masereeuw R; Russel FG
Transl Res; 2013 Dec; 162(6):398-409. PubMed ID: 24036158
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective Inhibition of Methotrexate Excretion by Glucuronides of Nonsteroidal Anti-inflammatory Drugs via Multidrug Resistance Proteins 2 and 4.
Kawase A; Yamamoto T; Egashira S; Iwaki M
J Pharmacol Exp Ther; 2016 Feb; 356(2):366-74. PubMed ID: 26659924
[TBL] [Abstract][Full Text] [Related]
14. Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid.
Maher JM; Aleksunes LM; Dieter MZ; Tanaka Y; Peters JM; Manautou JE; Klaassen CD
Toxicol Sci; 2008 Dec; 106(2):319-28. PubMed ID: 18757529
[TBL] [Abstract][Full Text] [Related]
15. Anti-arthritic effect of β-caryophyllene and its ameliorative role on methotrexate and/or leflunomide-induced side effects in arthritic rats.
El-Sheikh SMA; Abd El-Alim AEF; Galal AAA; El-Sayed RG; El-Naseery NI
Life Sci; 2019 Sep; 233():116750. PubMed ID: 31408659
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
[TBL] [Abstract][Full Text] [Related]
17. The importance of inhibition of a catabolic pathway of methotrexate metabolism in its efficacy for rheumatoid arthritis.
Morgan SL; Baggott JE
Med Hypotheses; 2019 Jan; 122():10-15. PubMed ID: 30593388
[TBL] [Abstract][Full Text] [Related]
18. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
Sharp JT; Strand V; Leung H; Hurley F; Loew-Friedrich I
Arthritis Rheum; 2000 Mar; 43(3):495-505. PubMed ID: 10728741
[TBL] [Abstract][Full Text] [Related]
19. CP-25 combined with MTX/ LEF ameliorates the progression of adjuvant-induced arthritis by the inhibition on GRK2 translocation.
Yang X; Zhao Y; Jia X; Wang C; Wu Y; Zhang L; Chang Y; Wei W
Biomed Pharmacother; 2019 Feb; 110():834-843. PubMed ID: 30557832
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models.
Wang Z; Zhou Q; Kruh GD; Gallo JM
Drug Metab Dispos; 2011 Nov; 39(11):2155-61. PubMed ID: 21841039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
